A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease

Overview of attention for article published in Respiratory Research, November 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (75th percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

So far, Altmetric has seen 16 X posts from 15 X users, with an upper bound of 19,964 followers.

RT @tipssovetorax: Revefenacin un nuevo anticolinergico de acción prolongada para el EPOC. Que tan efectivo y seguro es? @mlaucho1 @betul…

RT @tipssovetorax: Revefenacin un nuevo anticolinergico de acción prolongada para el EPOC. Que tan efectivo y seguro es? @mlaucho1 @betul…

RT @tipssovetorax: Revefenacin un nuevo anticolinergico de acción prolongada para el EPOC. Que tan efectivo y seguro es? @mlaucho1 @betul…

Revefenacin un nuevo anticolinergico de acción prolongada para el EPOC. Que tan efectivo y seguro es? @mlaucho1 @betuliochacin @benitorh @surfactante https://t.co/7XQOx5ErBP

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 12 additional X posts.